Cognition Therapeutics annual shares outstanding
2020
2021
2022
2023
2024
2025
Cognition Therapeutics Shares Outstanding History (CGTX)
Cognition Therapeutics reported 88.9M shares outstanding at the end of fiscal 2025.
View full Cognition Therapeutics company overviewCognition Therapeutics annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 88.9M | 29.0M | +48.53% |
| 2024 | 2024-12-31 | 59.9M | 27.7M | +86.08% |
| 2023 | 2023-12-31 | 32.2M | 3.2M | +10.95% |
| 2022 | 2022-12-31 | 29.0M | 6.8M | +30.42% |
| 2021 | 2021-12-31 | 22.2M | 21.7M | +4025.89% |
| 2020 | 2020-12-31 | 538,793 | — | — |
Cognition Therapeutics quarterly shares outstanding
Q4.20
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 95.1M | 30.1M | +46.32% |
| Q1 2026 | 2026-03-31 | 89.4M | 27.4M | +44.18% |
| Q4 2025 | 2025-12-31 | 88.9M | 29.0M | +48.53% |
| Q3 2025 | 2025-09-30 | 88.3M | 47.5M | +116.31% |
| Q2 2025 | 2025-06-30 | 65.0M | 24.9M | +61.95% |
| Q1 2025 | 2025-03-31 | 62.0M | 22.0M | +54.99% |
| Q4 2024 | 2024-12-31 | 59.9M | 27.7M | +86.08% |
| Q3 2024 | 2024-09-30 | 40.8M | 10.4M | +34.16% |
| Q2 2024 | 2024-06-30 | 40.1M | 9.8M | +32.44% |
| Q1 2024 | 2024-03-31 | 40.0M | 10.7M | +36.58% |
| Q4 2023 | 2023-12-31 | 32.2M | 3.2M | +10.95% |
| Q3 2023 | 2023-09-30 | 30.4M | 6.4M | +26.90% |
| Q2 2023 | 2023-06-30 | 30.3M | 7.7M | +34.02% |
| Q1 2023 | 2023-03-31 | 29.3M | 6.7M | +29.67% |
| Q4 2022 | 2022-12-31 | 29.0M | 6.8M | +30.42% |
| Q3 2022 | 2022-09-30 | 24.0M | 23.4M | +3791.74% |
| Q2 2022 | 2022-06-30 | 22.6M | — | — |
| Q1 2022 | 2022-03-31 | 22.6M | — | — |
| Q4 2021 | 2021-12-31 | 22.2M | 21.7M | +4025.89% |
| Q3 2021 | 2021-09-30 | 615,907 | — | — |
| Q4 2020 | 2020-12-31 | 538,793 | — | — |
Cognition Therapeutics shares outstanding trends
Over the last five fiscal years, Cognition Therapeutics's shares outstanding moved from 538,793 to 88.9M, a change of 88.4M. The latest reported quarter, Q2 2026, shows 95.1M.
About the metric
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
Calculation and source
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when a stock-split conversion ratio is reported directly or evidenced by a later filing’s restated historical share balance. After repeated reverse splits, an old period can represent less than one current-basis share; this is a split-adjusted equivalent, not a literal historical certificate count. Values remain as reported when no reliable split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Cognition Therapeutics source filings ↗Community posts
Cognition aligns with FDA on pivotal Lewy body dementia trial
Cognition Therapeutics ($CGTX) said it reached agreement with the FDA on key elements of a planned pivotal Phase 3 study of zervimesine, also known as CT1812, in dementia with Lewy bodies. The proposed trial would compare a 100-milligram da ...
